| Similar Articles |
|---|
 |
Pharmaceutical Executive
November 1, 2006
Patrick Clinton |
Man in a Hurry Bureaucratic? Bayer? Not if you ask Arthur Higgins. In just over two years, the head of Bayer HealthCare has proved that pharma can be a quick and nimble business.   |
The Motley Fool
November 30, 2006
Brian Lawler |
Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note. |
BusinessWeek
April 15, 2010
Naomi Kresge |
As the Pill Turns 50, a Rivalry Heats Up With underserved markets in Asia beckoning, Teva is taking on Bayer, the leader in oral contraceptives |
The Motley Fool
October 23, 2007
Brian Orelli |
Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth. |
| AskMen.com |
Birth Control For Men A leafy shrub growing in an Indonesian forest is home to a chemical that could provide male birth control in pill form. |
ifeminists
April 20, 2005
Glenn Sacks |
Do Women Really Want a Male Birth Control Pill? Researchers are close to perfecting a male contraceptive but it may encounter resistance from women unwilling to give up reproductive control. |
The Motley Fool
November 29, 2004
Brian Gorman |
Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year. |
The Motley Fool
March 27, 2006
Rich Smith |
Bayer Prescribes Itself a Buyout Bayer's bid for Schering trumped an earlier $17.5 billion offer from yet another German powerhouse, Merck KGaA. Why would Bayer pay so much for Schering? Investors, take note. |
The Motley Fool
November 27, 2007
Brian Orelli |
Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note. |
| AskMen.com |
The Injectable Vasectomy: Would You Try It? Are you ready to throw in the towel on condoms but leery of the old "snip snip?" An Indian scientist may have just the solution you're looking for. |
Pharmaceutical Executive
January 1, 2007
Sarah Houlton |
Global Report: No Satisfaction Germans on both sides of the political spectrum agree that their country's healthcare system needs reform. The latest attempt at change, though, doesn't really meet either side's needs. |
American Family Physician
July 1, 2006
Lesnewski & Prine |
Initiating Hormonal Contraception Physicians can help patients improve their use of birth control by providing anticipatory guidance about the most common side effects, giving comprehensive information about available choices, and honoring women's preferences. |
The Motley Fool
September 5, 2006
Brian Gorman |
Bayer Rising? Bayer still has some hoops to jump through before it's in tip-top shape, but the company has some tantalizing opportunities. Investors, it's not too early to put the German conglomerate on the watch list. |
The Motley Fool
July 24, 2007
Brian Orelli |
No Pharma Love for Schering A doubling of earnings, but no jump in stock price? Schering investors, take note. |
American Family Physician
February 15, 2004 |
New Contraceptive Options A study of different forms and methods of contraception. |
Chemistry World
May 9, 2014
Andy Extance |
Bayer wins race to buy Merck & Co consumer care Germany's Bayer has won a bidding contest for US giant Merck & Co's consumer care business unit, seemingly thanks to a heart drug collaboration sweetener. |
American Family Physician
October 15, 2000 |
Progestin-Only Contraceptives What is a progestin-only contraceptive?... How does the progestin-only contraceptive work?... Is the progestin-only pill better than regular birth control pills?... If I use the progestin-only pill, can I still get pregnant?... Does the progestin-only pill have any disadvantages? |
The Motley Fool
May 28, 2008
Brian Lawler |
A Strange Novartis MS Drug Story Novartis gets approval for a drug with an interesting history. |
The Motley Fool
August 7, 2007
Brian Orelli |
Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering. |
Chemistry World
March 12, 2007 |
Akzo Nobel Sells Medicines Business to Schering Plough US drug giant Schering-Plough is to buy Dutch chemical company Akzo Nobel's pharmaceuticals and animal health business, Organon BioSciences, for 11 billion euros. |
The Motley Fool
July 24, 2007
Brian Lawler |
Schering Doesn't Slow Schering-Plough continues its strong sales and earnings growth, but it has a big acquisition to digest in coming quarters. |
BusinessWeek
May 14, 2007
Arlene Weintraub |
Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience |
Chemistry World
July 5, 2012 |
Bayer buys crop protection firm for $425m German chemical and healthcare giant Bayer has struck a deal to buy US firm AgraQuest, which makes pest control products based on 'natural' or specially bred microorganisms. |
American Family Physician
August 15, 2004
David G. Weismiller |
Emergency Contraception Advance provision of this type can increase its use significantly without adversely affecting the use of routine contraception. |
The Motley Fool
March 3, 2005
Brian Gorman |
Bayer Heals Itself The latest earnings report suggests things are looking up -- and drug development may soon yield more good news for investors. |
The Motley Fool
March 5, 2008
Brian Orelli |
Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned. |
American Family Physician
May 15, 2002
Sarina Schrager |
Abnormal Uterine Bleeding Associated with Hormonal Contraception Abnormal uterine bleeding is a common but rarely dangerous side effect of hormonal contraception. It is, however, a major cause for the discontinuation of hormonal contraception and the resultant occurrence of unplanned pregnancy... |
The Motley Fool
September 22, 2008
Brian Orelli |
Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out? |
Nurse Practitioner
March 2010
Beth Kelsey |
Contraceptive Considerations for Obese Women It is important for nurse practitioners to be equipped with the most up-to-date knowledge to provide evidence-based care individualized to each woman's contraceptive needs and health profile. |
The Motley Fool
November 4, 2009
Brian Orelli |
An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem. |
The Motley Fool
July 20, 2004
Brian Gorman |
Bayer Reshuffles Business Bayer, one of Germany's most venerable industrial names, is revamping its house. Seemingly in one fell swoop, the company is spinning off its Lanxess chemicals and polymers unit and buying Roche's over-the-counter-drugs business. |
Chemistry World
September 23, 2014
Andy Extance |
Bayer to sever polymer arm The German chemical giant has announced plans to spin off its MaterialScience business as a new company within 12 -- 18 months. |
Chemistry World
October 31, 2012
Andrew Turley |
Bayer spends $1.2bn on supplement maker German healthcare giant Bayer has struck a deal to buy Schiff Nutrition, a US company specializing in vitamins and nutritional supplements, for $1.2 billion. |
The Motley Fool
December 21, 2010
Brian Orelli |
4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday. |
BusinessWeek
April 16, 2007
Arlene Weintraub |
Big Pharma's Animal Spirits Sales of medicine for pets and livestock are giving drugmakers a welcome boost. |
The Motley Fool
April 12, 2011
Brian Orelli |
Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets. |
Pharmaceutical Executive
October 1, 2008
Patrick Clinton |
Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there? |
The Motley Fool
August 29, 2006
S.J. Caplan |
Bayer's Crop Headache The company's second-quarter earnings are up while crops drag. Investors, take note. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Entrepreneur
March 2010
Jennifer Wang |
Girl Power Why women in business have suffered fewer casualties than men. |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
The Motley Fool
October 23, 2006
Brian Lawler |
The New Schering-Plough Possibly the cheapest large-cap pharmaceutical company compared with its growth potential, the new Schering-Plough is no dirt. Investors craving only one domestic large-cap pharma stock might be happiest with the new Schering. |
Pharmaceutical Executive
April 1, 2007 |
Deals: No IPO for Organon Akzo Nobel's plans to spin off its Organon Biosciences unit... Oxford BioMedica will acquire the privately held Oxxon Therapeutics... Jazz Pharmaceuticals has filed a registration statement with the SEC for... etc. |
Bio-IT World
November 2005
Charles Firneno |
The Information Value Chain By looking at the evolution of pharma's information networks, strategies can be designed for IT solutions such as CRM, CTMS, AERSs, and business analytics software to deliver the highest possible value. |
American Family Physician
November 15, 2000
Randy Ellen Wertheimer |
Emergency Postcoital Contraception Emergency postcoital contraception, a method used to prevent pregnancy after unprotected sexual intercourse, is a highly effective but underutilized birth control option.... |
Pharmaceutical Executive
September 1, 2008 |
Place Your Bets The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
